Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 30;2(2):52-61.
doi: 10.1002/bjs5.46. eCollection 2018 Apr.

Meta-analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma

S Schorn  1 , I E Demir  1 , N Samm  1 , F Scheufele  1 , L Calavrezos  1 , M Sargut  1 , R M Schirren  1 , H Friess  1 , G O Ceyhan  1
Affiliations
Review

Meta-analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma

S Schorn et al. BJS Open. .

Abstract

Background: Neoadjuvant therapy may increase the rate of radical tumour resection in patients with pancreatic cancer. Its impact on tumour recurrence has not been investigated fully. This study aimed to assess the impact of neoadjuvant therapy on patterns of recurrence.

Methods: A systematic review was performed of articles identified through the PubMed, Scopus, Embase, Ovid and Google Scholar databases that analysed the relationship between neoadjuvant therapy and recurrence published to January 2016. The main endpoint was overall tumour recurrence. Other endpoints included local recurrence, any kind of distant, hepatic, pulmonary or peritoneal metastasis.

Results: A total of 4257 citations were reviewed. Twelve observational studies comprising 1365 patients were analysed. Neoadjuvant therapy significantly reduced the risk of overall (risk ratio (RR) 0·82, 95 per cent c.i. 0·74 to 0·90; P < 0·001) and local (RR 0·42, 0·32 to 0·55; P < 0·001) recurrence. Neoadjuvant therapy did not reduce the risk of any kind of distant (RR 1·02, 0·91 to 1·14; P = 0·78), hepatic (RR 0·86, 0·68 to 1·10; P = 0·23), pulmonary (RR 0·99, 0·37 to 2·66; P = 0·98) or peritoneal (RR 0·88, 0·57 to 1·38; P = 0·58) metastasis.

Conclusion: Neoadjuvant therapy reduced the risk of local recurrence but not that of distant metastasis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PRISMA flow diagram for the systematic review and meta‐analysis
Figure 2
Figure 2
Forest plot comparing overall tumour recurrence following the use of neoadjuvant therapy versus primary surgery in patients with pancreatic cancer. A Mantel–Haenszel fixed‐effect model was used for meta‐analysis. Risk ratios are shown with 95 per cent confidence intervals. RPC, resectable pancreatic cancer; BRPC, borderline resectable pancreatic cancer; LAPC, locally advanced pancreatic cancer
Figure 3
Figure 3
Forest plot comparing a local tumour recurrence and b distant metastasis of any kind following the use of neoadjuvant therapy versus primary surgery in patients with pancreatic cancer. A Mantel–Haenszel fixed‐effect model was used for meta‐analysis. Risk ratios are shown with 95 per cent confidence intervals. RPC, resectable pancreatic cancer; BRPC, borderline resectable pancreatic cancer; LAPC, locally advanced pancreatic cancer
Figure 4
Figure 4
Funnel plot of publication bias in meta‐analyses of a overall recurrence (11 studies), b local recurrence (11 studies), c no recurrence (10 studies) and d distant metastasis (11 studies). RR, risk ratio; RPC, resectable pancreatic cancer; BRPC, borderline resectable pancreatic cancer; LAPC, locally advanced pancreatic cancer
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7–30. - PubMed
    1. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997; 21: 195–200. - PubMed
    1. Gebhardt C, Meyer W, Reichel M, Wünsch PH. Prognostic factors in the operative treatment of ductal pancreatic carcinoma. Langenbecks Arch Surg 2000; 385: 14–20. - PubMed
    1. Bradley EL III. Long‐term survival after pancreatoduodenectomy for ductal adenocarcinoma: the emperor has no clothes? Pancreas 2008; 37: 349–351. - PubMed
    1. Hohenberger W, Kastl S. [Neoadjuvant and adjuvant therapy of ductal pancreatic carcinoma.] Zentralbl Chir 2000; 125: 348–355. - PubMed